SCHEMBL23744192

SCHEMBL23744192

C[C@@H]1CN(c2cnc3cc(F)ccc3n2)C[C@H](C)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
HRH4 Q9H3N8 3/20 0.42
HCRTR1 O43613 6/20 0.41
HCRTR2 O43614 6/20 0.41
PIK3CA P42336 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC2 Q92769 1/20 0.41
HTR3A P46098 1/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SORD Q00796 1/20 0.37
EIF2AK4 Q9P2K8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30345676 1.00 MEN1 (0.43) MEN1NPC1RAB9AKMT2AHRH4
SCHEMBL30345513 1.00 MEN1 (0.43) MEN1NPC1RAB9AKMT2AHRH4
SCHEMBL23744193 1.00 MEN1 (0.43) MEN1NPC1RAB9AKMT2AHRH4
Hydrochloric Acid SCHEMBL23728072 0.99 HRH4 (0.43) MEN1NPC1RAB9AKMT2AHRH4
Hydrochloric Acid SCHEMBL30073589 0.99 HRH4 (0.43) MEN1NPC1RAB9AKMT2AHRH4
SCHEMBL23744797 0.86 ACVR1 (0.47) MEN1NPC1RAB9AKMT2AHRH4
SCHEMBL10271537 0.85 PDE10A (0.44) HRH4HCRTR1HCRTR2PIK3CAHTR3A
SCHEMBL14143557 0.84 HRH4 (0.42) HRH4HCRTR1HCRTR2PIK3CAHTR3A
SCHEMBL10219263 0.84 HRH4 (0.61) NPC1RAB9AKMT2AHRH4HCRTR1
SCHEMBL10219265 0.83 EIF2AK4 (0.48) HRH4HCRTR1HCRTR2PIK3CAEIF2AK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 MEN1 1049/4885NPC1 1236/4885RAB9A 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.